Epidemiology

Your Organisational Guidance

ebpracticenet urges you to prioritise the following organisational guidance:

MaagklachtenPublished by: NHGLast published: 2025

Data for incidence and prevalence of gastritis are difficult to measure as many cases may be acute or transient, but prevalence of some subtypes of gastritis has been described. Dyspeptic symptoms are reported in 10% to 20% of patients taking non-steroidal anti-inflammatory drugs (NSAIDs), although the prevalence may range from 5% to 50%.[17][18]​ In the US, dyspeptic symptoms affect up to 25% of the population; non-ulcer dyspepsia (including gastritis) contributes to the diagnosis in about 50% of patients referred for upper endoscopy.[19]

The prevalence of autoimmune gastritis has been reported to range from 0.1% to 2%, with a higher prevalence noted in women and people aged 60 years and older.[20]​ North European or Scandinavian ancestry is a recognised risk factor for autoimmune gastritis.[9] Non-white individuals may have an earlier onset of autoimmune gastritis compared with white individuals.[20]

The prevalence of Helicobacter pylori infection is higher in developing countries and is impacted by a multitude of factors, including geography, age, strain virulence, environmental factors, and socioeconomic status.[21][22]​​​ A global decline in H pylori infections has been reported by one meta-analysis.[23]​ In North America, although the occurrence of H pylori has subsided over time, the infection prevalence is still 30% to 40%.[3]​ Non-white races and ethnicities, those living in poor sanitary conditions, and immigrants from endemic countries are more frequently affected.[3]

Use of this content is subject to our disclaimer